Effectiveness of sporobakterin probiotic in patients with chronic hepatitis C

Abstract

Aim. To assess the effect of Sporobacterin probiotic for correction of bowel dysbiosis syndrome in patients with chronic hepatitis C. Methods. Bacteriological examination of stool samples from 100 patients with chronic hepatitis C was performed to detect the bowel dysbiosis syndrome. Some immunity parameters such as CD3+, CD4+, CD8+ and CD19+ blood counts, serum immunoglobulin A, G and M levels, phagocytic coefficient and phagocytic index, metabolic activity of neutrophils, serum circulating immune complex levels were also examined. Viral load was assessed using a polymerase chain reaction. These measurements were repeatedly done in patients who received Sporobacterin (main group, 50 patients) and compared to results of 25 patients taking Bifidumbacterin as well as 25 patients who were not taking probiotics. Results. Bowel dysbiosis syndrome was present in 85% of patients with hepatitis C. In patients taking Sporobacterin during three months, moderate degree of dysbiosis significantly reduced from 1.88±0.15 to 0.38±0.1. Majority of patients from this group recovered intestinal microbiota - 72±6.35%, while initially only 14±4.91% of these patients had normal intestinal microbiota level. Before the treatment 38±6.86% of patients were diagnosed with III degree of bowel dysbiosis syndrome, compared to absence of such diagnoses after the treatment period. After 1 month of the treatment, number of patients with normal count of bifidobacteria in 1 g of stool was significantly higher in the group treated with Sporobacterin (50±7.07%), compared to the group treated with Bifidumbacterin (24±8.54%), as well as number of patients with marked reduction of lactobacteria in 1 g of stool (0 vs 16±7.3%). There was a marked and significant reduction of viral load in patients treated with Sporobacterin, which decreased from 8.3±3.46×106 copies/ml initially to 0.8±0.24×106 copies/ml after 1 month of treatment and to 0.094±0.022×106 copies/ml after 3 months of treatment. After 3 months of treatment the number of patients with the following conditions reduced significantly: elevated leukocyte count from 32.5±7.41 to 6.25%, decreased CD8+ count - from 42.5±7.82 to 6.25%, increased serum immunoglobulin G level - form 25±6.85 to 18.75±9.76%. Conclusions. Use of Sporobacterin for treatment of bowel dysbiosis syndrome in patients with chronic hepatitis C is highly effective and superior to treatment with Bifidumbacterin, Sporobacterin may modulate the immune response and decrease the viral load in patients with chronic hepatitis C.

Keywords

chronic hepatitis C / intestinal microbiota / bacterial therapy / Sporobacterin

References

[1] Гранитов В.М., Хорошилова И.А., Шабанова С.В. Нарушение микробиоценоза кишечника у больных парентеральными вирусными гепатитами // Эпидемиол. и инфекц. бол. - 2002. - №6. - С. 30-32.

[2] Ершова О.Н., Шахгильдян И.В., Кузин С.Н. Эпидемиология HCV-инфекции // Гепатол. форум. - 2006. - №1. - С. 6-9.

[3] Жданов К.В., Волжанин В.М., Гусев Д.А. Вирусные гепатиты: клиника, диагностика, лечение / Под ред. Ю.В. Лобзина. - СПб.: Фолиант, 2006. - 183 с.

[4] Раков А.Л., Лобзин Ю.В., Горбаков В.В. Актуальные проблемы гепатологии: эпидемиология вирусных гепатитов // Воен.-мед. ж. - 2002. - Т. 323. - С. 96.

[5] Серов В.В., Апросина З.Г. Хронический вирусный гепатит. - М.: Медицина, 2002. - 384 с.

[6] Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). - М.: ВУНМЦ Росздрава, 2003. - 349 с.

[7] Шульпекова Ю.О. Применение пробиотиков в клинической практике // Рус. мед. ж. - 2003. - Т. 5, №1. - С. 28-32.

[8] Alric L., Thebault S., Peron J.M. Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis С virus genotype 1 // J. Viral. Hepat. - 2006. - Vol. 13. - P. 139-144.

RIGHTS & PERMISSIONS

Knyaz’kina O.V., Kagan Y.D., Skachkov M.V.